Alcon AG vs KraneShares CSI China Internet ETF — how do they compare? Alcon AG trades at $73.87 (market cap $36.44B), while KraneShares CSI China Internet ETF trades at $27.54. The key difference: Alcon AG pays a 0.48% dividend while KraneShares CSI China Internet ETF pays none, and Alcon AG is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| ALC | KWEB | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.12 | $42.94 |
52-Week Low | $62.02 | $23.63 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
KWEB trades at $27.525, down 5.48% today amid pressure on Chinese stocks. The technical outlook is bullish with moving averages supporting an uptrend, while oscillators are neutral. Recent news highlights institutional buying and China's strong export growth, though regulatory risks persist.
The ETF offers exposure to China's internet and AI sectors, trading near 52-week lows with potential for rebound driven by AI growth and government support. Key risks include U.S.-China tensions and domestic economic volatility, requiring careful risk assessment for investors.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →